Form 4: OnKure Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Dylan Hartley, Chief Scientific Officer of OnKure Therapeutics, acquires stock options.
Summary
- Dylan Hartley, the Chief Scientific Officer of OnKure Therapeutics, acquired 137,603 employee stock options on October 4, 2024.
- The exercise price of these options is $18.2.
- The options vest over time, with 1/4th vesting on June 9, 2025, and then 1/48th vesting monthly thereafter, contingent on continued service.
- The options expire on October 3, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the executive's continued contribution. There are no explicitly negative aspects in the document.
Positives
- The acquisition of stock options by a key executive aligns their interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the Chief Scientific Officer.
Risks
- The value of the stock options is dependent on the future performance of OnKure Therapeutics' stock.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the options suggests an expectation of continued service and contribution from the executive.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies, similar to companies like Amgen, Gilead Sciences, and Biogen.
- Vesting schedules, such as the one described in the document, are also typical, designed to incentivize long-term commitment and performance.
Stakeholder Impact
- The acquisition of stock options by a key executive can positively impact shareholders by aligning management's interests with the company's long-term success.
- Employees may view this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 10/04/2024 | Date of the transaction: Dylan Hartley acquired stock options. |
| 06/09/2025 | First vesting date: 1/4th of the shares subject to the option vest. |
| 10/03/2034 | Expiration date of the stock options. |
| 10/08/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.